Platform's potential for early-stage detection cannot be ignored, says Owlstone Medical CEO

Sometimes a device or diagnostic comes along that even the most drug-centric of pharma companies cannot afford to ignore, but when this innovation threatens to establish a new diagnostic modality that sits alongside blood and urine, it is definitely worth taking notice.

Pharma needs to be aware of Owlstone Medical’s Breath Biopsy platform, a non-invasive system that captures and analyzes breath samples for the presence of trace chemicals related to disease activity, not just because of opportunities for pairing patients with appropriate therapies. The system could also go a long way to cutting out the need for some of the very therapies that pharma’s billions are riding on.

"Ultimately the thing that we need to do in cancer is to get better at early detection"